Development of Mast Uri^® Plates for Urinary Tract Infections AMR Screening: Carbapenemase-Producing Enterobacteriaceae (CPE)

In celebration of International Pathology Day 2024, Mast Group is pleased to announce the submission of our latest research poster to the Royal College of Pathology virtual conference on antimicrobial resistance (AMR).

As AMR remains a pressing global health challenge, we continue to focus on the development of rapid, precise diagnostic tools to support clinicians in managing infections effectively. An innovative Mast Uri^® Plate is being designed to screen for carbapenemase-producing Enterobacteriaceae (CPE), a highly resistant group of bacteria that complicates the treatment of urinary tract infections (UTIs) and poses a significant threat to public health.

Our recent study shown below showcases the high sensitivity and specificity of potential Mast Uri^® Plate formulations in detecting CPE through advanced formulations that selectively inhibit non-target organisms, ensuring accurate AMR screening.